Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter
This article was originally published in The Pink Sheet Daily
Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.
You may also be interested in...
Alabama Republican Robert Aderholt takes over as FDA appropriations subcommittee chair after running homeland security subcommittee; Mikulski to run Senate Appropriations Committee.
A continuing resolution does not specifically allow FDA to spend the fees, but the generic drug backlog and biosimilar product development fees are expected to be available.
A new guidance includes preliminary estimates of backlog, application and drug master file fees under the new generic drug user fee program. However, the agency must wait for Congress to pass an FY 2013 appropriations bill or continuing resolution with language allowing it to collect the new revenue.